Comprehensive metabolomics expands precision medicine for triple-negative breast cancer.
Xiao Y, Ma D, Yang YS, Yang F, Ding JH, Gong Y, Jiang L, Ge LP, Wu SY, Yu Q, Zhang Q, Bertucci F, Sun Q, Hu X, Li DQ, Shao ZM, Jiang YZ. · 2022
Read Comprehensive metabolomics expands precision medicine for triple-negative breast cancer. by Xiao Y, Ma D, Yang YS, Yang F, Ding JH, Gong Y, Jiang L, Ge LP, Wu SY, Yu Q, Zhang Q, Bertucci F, Sun Q, Hu X, Li DQ, Shao ZM, Jiang YZ. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9061756.txt.
Introduction
Xiao and co-authors built a metabolic atlas of triple-negative breast cancer, a form lacking the usual hormone targets. They profiled 330 tumor samples and 149 paired normal tissues, covering both small molecules and lipids. The tumors fell into three metabolic subgroups, from fat-rich profiles to quiet ones with little disturbance. Layering this map over gene data refined the known subtypes.
Model tumors pointed to drug targets inside the pathways. Blocking one lipid signal slowed the androgen-driven subtype, and another metabolite drove high-risk tumors. The team released the dataset as a public resource for precision treatment.
Catalog record
| CREATOR | Xiao Y, Ma D, Yang YS, Yang F, Ding JH, Gong Y, Jiang L, Ge LP, Wu SY, Yu Q, Zhang Q, Bertucci F, Sun Q, Hu X, Li DQ, Shao ZM, Jiang YZ. |
|---|---|
| YEAR | 2022 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 70 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Comprehensive metabolomics expands precision medicine for triple-negative breast cancer By Yi Xiao, Ding Ma, Yun-Song Yang, Fan Yang, Jia-Han Ding, Yue Gong, Lin Jiang, Li-Ping Ge, Song-Yang Wu, Qiang Yu, Qing Zhang, François Bertucci Published in: Cell Research DOI: 10.1038/s41422-022-00614-0 ABSTRACT Abstract Metabolic reprogramming is a hallmark of cancer. However, systematic characterizations of metabolites in triple-negative breast cancer (TNBC) are still lacking. Our study profiled the polar metabolome and lipidome in 330 TNBC samples and 149 paired normal breast tissues to construct a large metabolomic atlas of TNBC. Combining with previously established transcriptomic and genomic data of the same cohort, we conducted a comprehensive analysis linking TNBC metabolome to genomics. Our study classified TNBCs into three distinct metabolomic subgroups: C1, characterized by the enrichment of ceramides and fatty acids; C2, featured with the upregulation of metabolites related to oxidation reaction and glycosyl transfer; and C3, having the lowest level of metabolic dysregulation. Based on this newly developed metabolomic dataset, we refined previous TNBC transcriptomic subtypes and identified some crucial subtype-specific metabolites as potential therapeutic targets. The transcriptomic luminal androgen receptor (LAR) subtype overlapped with metabolomic C1 subtype. Experiments on patient-derived organoid and xenograft models indicate that targeting sphingosine-1-phosphate (S1P), an intermediate of the ceramide pathway, is a promising therapy for LAR tumors. Moreover, the transcriptomic basal-like immune-suppressed (BLIS) subtype contained two prognostic metabolomic subgroups (C2 and C3), which could be distinguished through machine-learning methods. We show that N-acetyl-aspartyl-glutamate is a crucial tumor-promoting metabolite and potential therapeutic target for high-risk BLIS tumors. Together, our study reveals the clinical significance of TNBC metabolomics, which can not only optimize the transcriptomic subtyping system, but also suggest novel therapeutic targets. This metabolomic dataset can serve as a useful public resource to promote precision treatment of TNBC. Subject terms: Breast cancer, Cancer metabolism INTRODUCTION Triple-negative breast cancer (TNBC) is a subset of breast cancer defined by the lack of expression of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2.1 Clinical management of TNBC is a great challenge because of its high incidence of visceral metastases and the lack of well-recognized therapeutic targets.1 TNBC has been considered as a highly heterogeneous disease.2–4 Our previous study presented a genomic and transcriptomic landscape of 465 Chinese patients with TNBC and classified TNBCs into four transcriptomic subtypes with distinct molecular features.4 We further revealed the potential therapeutic targets of each transcriptomic subtype and conducted an umbrella trial (FUTURE, ClinicalTrials.gov, number: NCT03805399) on metastatic TNBCs to evaluate the treatment efficacy regarding to these targets.5 The FUTURE trial exhibited an encouraging objective response rate (ORR) of 29%, which was significantly higher than the ORRs of traditional chemotherapies (5%–15%).6,7 However, the treatment outcomes of corresponding targeted therapies did not reach our full expectation, especially for transcriptomic basal-like immune-suppressed (BLIS) and luminal androgen receptor (LAR) tumors. For example, CDK4/6, androgen receptor and mTOR inhibitors did not perform as well as expected in LAR tumors. Therefore, we need to seek for a more multilayered understanding of TNBC for new target identification. As an important hallmark of cancer, metabolic reprogramming in TNBC is worthy of further exploration. Previously, the mRNA expression level of metabolic genes were usually interpreted as the activity of corresponding metabolic pathways.8,9 Our recent study used the transcriptomic data of metabolic genes to investigate the metabolic features of TNBC.9 This study revealed that TNBCs could be classified into three metabolic-gene-based subtypes with distinct dependency on lipid metabolism and glycolysis. We further proposed therapeutic strategies targeting classic energy metabolism and developed combination therapies using glycolysis inhibitors together with immune checkpoint inhibitors.9 However, metabolic research using transcriptomic data still has limitations. First, the regulation of metabolism is a complex process. The abundance of metabolites might be more reliable for metabolic flux analysis than the mRNA expression of metabolic genes. Second, some crucial metabolites that are not in the classical energy metabolism pathways might be ignored, as previous transcriptomic data-based metabolic studies mainly focused on energy metabolism. Therefore, a more direct illustration of metabolism through analyzing the abundance of metabolites is required. The rapid development of high-throughput metabolomics techniques, such as global untargeted metabolomics and lipidomics, has paved the way for directly measuring the abundance of metabolites.10,11 Using these methods, we have achieved a deeper understanding of metabolic features in breast cancer.12–14 Previous studies demonstrated significant differences in glutamine and alanine metabolism between ER-positive and ER-negative breast cancers.12,13 Besides, the MYC-driven accumulation of 2-hydroxyglutarate has been shown to promote breast cancer progression.14 However, large-scale metabolomic researches connecting metabolism to TNBC genomics are still lacking. In this study, we profiled both the polar metabolome and lipidome of 330 TNBC samples to reveal the metabolomic landscape. We also integrated the metabolomics with previously established genomic and transcriptomic data to explore the potential metabolic targets for TNBCs, especially for transcriptomic BLIS and LAR tumors (Fig. 1a). [Figure: Overview of polar metabolome and lipidome detection in TNBC.a A sketch map showing the combined analysis using previously obtained transcriptomic data and the metabolomics data reported in this study for TNBC precision medicine. b A schematic summarizing the workflow for metabolite profiling. c The numbers and proportions of annotated polar metabolites and lipids in our study. Comparison of the number of annotated metabolites (d) and the number of samples (e) between our study and previous studies. BLIS, basal-like immunesuppressed; IM, immunomodulatory; LAR, luminal androgen receptor; MES, mesenchymal-like; MPS, metabolic-pathway-based subtypes; FA, fatty acids; GL, glycerolipids; GP, glycerophospholipids; SP, sphingolipids; ST, sterol lipids.] RESULTS Polar metabolite and lipid profiling of TNBC To comprehensively profile the TNBC metabolome, we used the sample set of our TNBC cohort containing sufficient quantities of high-quality fresh frozen tissues for polar metabolome and lipidome detection (Fig. 1b). Our metabolomic cohort included 330 TNBC samples and 149 paired normal breast tissues. We annotated a total of 594 polar metabolites and 1944 lipids (Fig. 1c; Supplementary information, Tables S1–S4). The data quality was checked with internal standards and quality control samples (Supplementary information, Data S1 and Fig. S1). We previously obtained transcriptomic data for 258 out of these 330 samples, among which 171 samples have whole-exome sequencing (WES) and somatic copy number alteration (SCNA) data as well (Supplementary information, Fig. S2). Generally, the newly developed TNBC metabolomic dataset is a large data resource regarding both the number of annotated metabolites and sample size (Fig. 1d, e).14–27 The metabolomic landscape of TNBC Using Benjamini–Hochberg-corrected Mann–Whitney U tests, we identified 452 metabolites (417 higher and 35 lower in tumor) displaying significant differences in abundance between tumor and normal samples (Fig. 2a, b). Among the dysregulated metabolites, some polar metabolites, especially metabolites related to oxidation reaction and glycosyl transfer (such as oxidized glutathione [GSSG] and uridine diphosphate glucose [UDPG]), were significantly enriched in tumors compared with normal tissues (Fig. 2a). Some lipids, such as phosphatidylinositols, fatty acids (FAs) and ceramides, were also enriched in TNBCs (Fig. 2b; Supplementary information, Fig. S3a). Moreover, we conducted the Spearman’s correlation analysis which illustrated that lipids belonging to the same subclass were closely correlated based on their abundances, we thus considered lipids of the same subclass as a whole for subsequent lipidomic analysis (Supplementary information, Fig. S3b). Furthermore, we performed KEGG metabolic pathway-based differential abundance (DA) analysis between tumor and normal tissues to